Innovis Asset Management’s DexCom DXCM Stock Holding History

Innovis Asset Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-37,345	Closed	-$4.8M	–	157
2023 Q2	$4.8M	Buy	+37,345	New	+$4.52M	1.77%	22

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Innovis Asset Management's DXCM Position: Q3 2023 in Review

Innovis Asset Management sold out of DexCom (DXCM) in Q3 2023, closing a stake of 37,345 shares — an estimated $4.8M sold.

Innovis Asset Management first reported a position in DXCM in Q2 2023 and held it in 1 quarter. The position peaked at $4.8M in Q2 2023. 902 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

Innovis Asset Management reported no remaining DexCom position as of Q3 2023 after selling out during the quarter.
Innovis Asset Management sold 37,345 DexCom shares in Q3 2023, an estimated $4.8M.
Innovis Asset Management first reported a position in DexCom in Q2 2023 and held it in 1 quarter.
Innovis Asset Management's DexCom position peaked at $4.8M in Q2 2023.
902 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.